A drug widely used to prevent excessive bleeding during heart surgery appears to raise the risk of dying in the five years afterward by nearly 50 percent, an international study found.

The researchers said replacing the drug — aprotinin, sold by Bayer AG under the brand name Trasylol — with other, cheaper medications for a year would prevent 10,000 deaths worldwide over the next five years.